Skip to content

Development of blocking traction device and its application in preventing blood spread of cancer cells in radical gastrectomy

Development of blocking traction device and its application in preventing blood spread of cancer cells in radical gastrectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036767
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

experimental group:D2 radical gastrectomy+ blocking traction

Sponsors

Huashan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The initial patients did not receive chemotherapy, radiotherapy or other anti-tumor treatment before the start of clinical trial; (2) The age ranged from 40 to 75 years old; (3) Male or non pregnant and lactating women; (4) Gastric adenocarcinoma was confirmed by pathology; (5) Patients with T stage T3 or above were judged by naked eyes during operation, and there was no distant metastasis. The standard D2 radical operation was feasible (AJCC, 7th Edition, 2010); (6) Function status: 0-1 (ECoG); (7) Sign informed consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) There was a history of other malignant tumors within 5 years; (2) Any M1 was found during the operation; (3) Patients with serious or uncontrolled medical diseases and infections (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, refractory hypertension, etc.); (4) Patients with seizures requiring treatment (e.g., steroids or antiepileptic therapy); (5) Patients with serious or uncontrollable mental illness; (6) Drug abuse and medical, psychological or social conditions may interfere with patients' participation in the study or affect the evaluation of research results; (7) Any unstable condition or situation that may endanger the patient's safety and compliance; (8) They are being treated with anticancer drugs from other clinical trials.

Design outcomes

Primary

MeasureTime frame
overall survival rate;

Countries

China

Contacts

Public ContactGuangjian Huang

Huashan Hospital Affiliated to Fudan University

gjhuang@fudan.edu.cn+86 13818385050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026